Filtered By:
Condition: Bleeding
Cancer: Cancer

This page shows you your search results in order of date. This is page number 19.

Order by Relevance | Date

Total 285 results found since Jan 2013.

Aspirin risks in perspective: A comparison against marathon running
Aspirin has public health potential to reduce the risk of ischaemic vascular events and sporadic cancer. One objection to the wider use of aspirin for primary prevention, however, is the undesirable effects of the medicine, which include increasing risk of bleeding and haemorrhagic stroke. Marathons also carry risks of serious events such as cardiac arrests and sudden death. Based on epidemiological estimates, a person running a marathon might be 20 to 100 times more likely to end up in hospital than a person who is taking an aspirin tablet. Yet the cumulative risk of daily aspirin use for primary prophylaxis may be import...
Source: Health Education Journal - June 10, 2014 Category: Health Management Authors: Morgan, G. Tags: Short Report Source Type: research

P-132 * bronchial sleeve resection or pneumonectomy for non-small-cell lung cancer: a propensity matched analysis of long-term survival and quality of life
Conclusions: During the 5-year follow-up, pneumonectomy and sleeve lobectomy showed no significant differences in cancer-specific survival or in quality of life. However, thereafter sleeve lobectomy patients showed better survival. This advocates the use of sleeve lobectomy in central non-small-cell lung cancer when feasible. Disclosure: No significant relationships.
Source: Interactive CardioVascular and Thoracic Surgery - June 9, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Andersson, S. E. M., Ilonen, I. K., Rasanen, J. V., Sihvo, E. I., Salo, J. A. Tags: SESSION VII: MODERATED POSTERS Source Type: research

NICE: 'schools should provide morning-after pill'
Conclusion Everyone makes mistakes, but if you find yourself relying on the morning-after pill as a regular method of contraception, you may want to speak to a healthcare professional about what would be the most suitable form of ongoing contraception for you to use. This could include methods that do not involve needing to take a daily pill, such as contraceptive patches, injections or an implant. However, none of these methods will protect you against sexually transmitted infections (STIs). Condoms are cheap, free of side effects and they will protect you against STIs such as chlamydia. For more information about your ...
Source: NHS News Feed - March 26, 2014 Category: Consumer Health News Tags: QA articles Pregnancy/child Source Type: news

Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.
CONCLUSIONS: We found no significant effects of systemic treatments compared with no intervention in preventing (a)symptomatic VTE in paediatric oncology patients with CVCs. However, this could be a result of the low number of included participants, which resulted in low power. In one CCT, which compared one systemic treatment with another systemic treatment, we identified a significant reduction in symptomatic VTE with the addition of LMWH to AT supplementation.All studies investigated the prevalence of major and/or minor bleeding episodes, and none found a significant difference between study groups. None of the studies ...
Source: Cochrane Database of Systematic Reviews - September 11, 2013 Category: Journals (General) Authors: Schoot RA, Kremer LC, van de Wetering MD, van Ommen CH Tags: Cochrane Database Syst Rev Source Type: research

Time trends in pulmonary embolism: A matter of age and gender
Venous thromboembolism (VTE) is the third most common cardiovascular disease . Pulmonary embolism (PE) is potentially lethal and is the most serious manifestation of VTE . Notably, PE is the leading preventable cause of death in hospitalized patients , and is the third most common cardiovascular cause of death after myocardial infarction and stroke in Western world . Risk factors for VTE and PE include old age, surgery, immobilization, trauma, fractures, cancer, pregnancy, puerperium, oral contraceptive pill (OCP) use, and hormone replacement therapy (HRT) . Genetic factors are also important in VTE risk and family history...
Source: Thrombosis Research - June 24, 2013 Category: Hematology Authors: Bengt Zöller Tags: Editorials Source Type: research

Aspirin For Primary Prevention Of Heart Attacks In Men: Eligibility Increases When Cancer Mortality Benefit Added
While aspirin has been shown to be effective in preventing heart attacks in men, it also increases the risk of gastrointestinal bleeding and possibly stroke, even at low doses. As such, national guidelines suggest that aspirin be used for prevention only in men at higher risk for cardiovascular events, so that the benefits of aspirin are greater than its adverse effects. Recent data suggest that aspirin may also be effective for reducing cancer deaths...
Source: Health News from Medical News Today - June 10, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news

Managing the Risks of Cardiac Therapy in Cancer Patients
The purpose of this review was to highlight the more commonly used cardiac medications that should be closely monitored or possibly discontinued during cancer therapy. Often, older cancer patients are taking multiple pharmacotherapy agents for the treatment or prevention of cardiac disease when they face decisions about cancer treatment. Concurrent administration of drugs can result either in increased toxicity or decreased efficacy of either therapy. The benefits of the cardiac medications must be weighed against the effects of cancer therapy, and the role of drug metabolism also must be considered. For example, the benef...
Source: Seminars in Oncology - April 1, 2013 Category: Cancer & Oncology Authors: Carol L. Chen, Rekha Parameswaran Tags: Marc L. Schwartz, ME, Guest Editor Source Type: research

Aspirin prophylaxis in people without prior cardiovascular disease does not lead to reductions in cardiovascular death or cancer mortality
Commentary on: Seshasai SR, Wijesuriya S, Sivakumaran R, et al.. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012;172:209–16. Context Prophylactic antiplatelet therapy with aspirin reduces the risk of non-fatal myocardial infarction (MI), non-fatal stroke and vascular death in patients with known cardiovascular disease (CVD) and is of net benefit. The absolute reduction in recurrent events significantly exceeds the increase in major bleeding.1 However, the role of aspirin in primary prevention of CVD is not clear. According to the Antithrombot...
Source: Evidence-Based Medicine - March 19, 2013 Category: Internal Medicine Authors: Farooq, M. U., Gorelick, P. B. Tags: Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Stroke, Hypertension, Prevention, Ischaemic heart disease Online articles Source Type: research

In recently postmenopausal women, HRT reduced a composite of death, MI, or heart failure at 10 years.
CONCLUSION In recently postmenopausal women, hormone replacement therapy reduced a composite of death, myocardial infarction, or heart failure after 10 years of therapy and an additional 6 years of follow-up.Hormone replacement therapy (HRT) vs no HRT in recently postmenopausal women†OutcomesEvent ratesAfter 10 y of therapyHRTNo HRTRRR (95% CI)NNT (CI)Death, MI, or HF‡3.2%6.5%50% (11 to 72)31 (22 to 144)At 16 yDeath, MI, or HF§6.6%11%37% (4 to 59)26 (17 to 251)†HF = heart failure; MI = myocardial infarction; other abbreviations defined in Glossary. RRR, NNT, and CI calculated from event rates and hazard ratios in ar...
Source: Annals of Internal Medicine - February 19, 2013 Category: Internal Medicine Authors: Cheung AM Tags: Ann Intern Med Source Type: research

Fatal Embolic Stroke Due to Non-Atherothrombotic Mobile Thrombi in the Carotid Artery during Gastric Cancer Chemotherapy: An Autopsy Case Report (P01.255)
CONCLUSIONS: Multiple etiologies for ischemic stroke may exist in cancer patients. A mobile thrombus in the carotid artery should be considered as a possible mechanism for arteriogenic stroke in the clinical settings of malignancy with hypercoagulability. Doppler ultrasonography is the most practical tool to identify these conditions.Disclosure: Dr. Yamada has nothing to disclose. Dr. Yoneda has nothing to disclose. Dr. Arakawa has nothing to disclose. Dr. Adachi has nothing to disclose. Dr. Gotoh has nothing to disclose. Dr. Takagi has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Yamada, A., Yoneda, J., Arakawa, C., Adachi, T., Gotoh, J., Takagi, M. Tags: P01 Cerebrovascular Disease I Source Type: research

Intravenous Alteplase for acute ischemic stroke in patients with current malignant neoplasm
Conclusions: Our experience suggests that IV thrombolysis does not appear to increase the risk of hemorrhagic complications in current non-metastatic cancer patients in absence of additional risk factors of bleeding. In addition, these patients showed clinical improvement after IV thrombolysis, although replication of our findings in a randomized controlled trial is required to confirm our results.
Source: Journal of the Neurological Sciences - January 14, 2013 Category: Neurology Authors: Manuel Cappellari, Monica Carletti, Nicola Micheletti, Giampaolo Tomelleri, Domenico Ajena, Giuseppe Moretto, Paolo Bovi Tags: Original Articles Source Type: research

Summary: International Kidney Cancer Symposium
Conclusions:  Ideal ischemia time is 20-25 minutes or less improves short and long term renal function.  >25 minutes carried 5 year risk of new onset stage 4 CKD No differences on GFR for cold vs. warm ischemia times Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.  No ischemia preserves renal function better than warm. Longer cold ischemia times were equivalent to shorter warm ischemia times. Quality and quantity of the remaining kidney is associated with ultimate renal function. Robotics in RCC Surgery Gennady Bratslavsky, MD The...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news